Literature DB >> 8691728

Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells.

N F van Det1, J van den Born, J T Tamsma, N A Verhagen, J H Berden, J A Bruijn, M R Daha, F J van der Woude.   

Abstract

Changes in heparan sulfate metabolism may be important in the pathogenesis of diabetic nephropathy. Recent studies performed on renal biopsies from patients with diabetic nephropathy revealed a decrease in heparan sulfate glycosaminoglycan staining in the glomerular basement membrane without changes in staining for heparan sulfate proteoglycan-core protein. To understand this phenomenon at the cellular level, we investigated the effect of high glucose conditions on the synthesis of heparan sulfate proteoglycan by glomerular cells in vitro. Human adult mesangial and glomerular visceral epithelial cells were cultured under normal (5 mM) and high glucose (25 mM) conditions. Immunofluorescence performed on cells cultured in 25 mM glucose confirmed and extended the in vivo histological observations. Using metabolic labeling we observed an altered proteoglycan production under high glucose conditions, with predominantly a decrease in heparan sulfate compared to dermatan sulfate or chondroitin sulfate proteoglycan. N-sulfation analysis of heparan sulfate proteoglycan produced under high glucose conditions revealed less di- and tetrasaccharides compared to larger oligosaccharides, indicating an altered sulfation pattern. Furthermore, with quantification of glomerular basement membrane heparan sulfate by ELISA, a significant decrease was observed when mesangial and visceral epithelial cells were cultured in high glucose conditions. We conclude that high glucose concentration induces a significant alteration of heparan sulfate production by mesangial cells and visceral epithelial cells. Changes in sulfation and changes in absolute quantities are both observed and may explain the earlier in vivo observations. These changes may be of importance for the altered integrity of the glomerular charge-dependent filtration barrier and growth-factor matrix interactions in diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691728     DOI: 10.1038/ki.1996.157

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

Authors:  David K Packham; Rory Wolfe; Anne T Reutens; Tomas Berl; Hiddo Lambers Heerspink; Richard Rohde; Sara Ivory; Julia Lewis; Itamar Raz; Thomas B Wiegmann; Juliana C N Chan; Dick de Zeeuw; Edmund J Lewis; Robert C Atkins
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

2.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Authors:  F N Ziyadeh; B B Hoffman; D C Han; M C Iglesias-De La Cruz; S W Hong; M Isono; S Chen; T A McGowan; K Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.

Authors:  S W Hong; M Isono; S Chen; M C Iglesias-De La Cruz; D C Han; F N Ziyadeh
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

4.  Effects of advanced glycosylation endproducts on perlecan core protein of glomerular epithelium.

Authors:  Tae-Sun Ha; Chang-Ju Song; Joon-Ho Lee
Journal:  Pediatr Nephrol       Date:  2004-09-22       Impact factor: 3.714

5.  Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway.

Authors:  J-M Zheng; J-M Zhu; L-S Li; Z-H Liu
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

6.  Protective Effects of Ethanolic Extract from Rhizome of Polygoni avicularis against Renal Fibrosis and Inflammation in a Diabetic Nephropathy Model.

Authors:  Jung-Joo Yoon; Ji-Hun Park; Yun-Jung Lee; Hye-Yoom Kim; Byung-Hyuk Han; Hong-Guang Jin; Dae-Gill Kang; Ho-Sub Lee
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

7.  Evaluation of Early Markers of Nephropathy in Patients with Type 2 Diabetes Mellitus.

Authors:  Pierina De Muro; Antonio Junior Lepedda; Gabriele Nieddu; Michela Idini; Hai Quy Tram Nguyen; Omar Lobina; Pietro Fresu; Marilena Formato
Journal:  Biochem Res Int       Date:  2016-01-24

8.  Disparate phospho-Smad2 levels in advanced type 2 diabetes patients with diabetic nephropathy and early experimental db/db mouse model.

Authors:  Lise Høj Thomsen; Morten Fog-Tonnesen; Lisbeth Nielsen Fink; Jenny Norlin; Amaya García de Vinuesa; Troels Krarup Hansen; Emile de Heer; Peter Ten Dijke; Alexander Rosendahl
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

9.  Age-dependent alteration of intraocular soluble heparan sulfate levels and its implications for proliferative diabetic retinopathy.

Authors:  Koji M Nishiguchi; Hiroaki Ushida; Daisuke Tomida; Shu Kachi; Mineo Kondo; Hiroko Terasaki
Journal:  Mol Vis       Date:  2013-05-29       Impact factor: 2.367

10.  Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys.

Authors:  Iris J Edwards; Janice D Wagner; Catherine A Vogl-Willis; Kenneth N Litwak; William T Cefalu
Journal:  Cardiovasc Diabetol       Date:  2004-04-29       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.